Business
Portfolio Company Update
Portfolio Company Update.
About this update from Tekcapital Plc
[{"type":"text","content":"\n \n \n RNS Number : 2531H\n Tekcapital plc\n 23 March 2020\n \n \n \n \n \n \n \n \n \n \n The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service (\"RIS\"), this inside information is now considered to be in the public domain.\n \n \n \n \n \n 23 March 2020\n \n \n \n \n \n Tekcapital plc\n \n \n (\"Tekcapital\" or the \"Company\")\n \n \n Portfolio Company Update\n \n \n \n \n \n New FDA Guidance to Expand the Availability of Respiratory Devices \n \n \n Tekcapital plc, (AIM: TEK) the UK intellectual property investment group focused on creating marketplace value from investing in university technology, notes that the United States\n Food and Drug Administration (the \"FDA\") has issued a new policy designed to expand the availability of respiratory devices, including Oxygen Concentrators, during the COVID-19 Pandemic which is potentially relevant to its portfolio company Belluscura plc. \n \n \n A copy of the FDA announcement may be found \n \n here\n \n .\n \n \n \n \n \n About Belluscura plc \n \n \n Belluscura is focused on developing novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Belluscura is developing innovative enriched oxygen treatment platforms that reduce the cost of treatment and increase available treatment options. To learn more about Belluscura, please visit \n \n www.belluscura.com\n \n . \n \n \n Tekcapital owns 18.9% of the share capital of Belluscura. \n \n \n Clifford M. Gross Ph.D., Executive Chairman of Tekcapital plc commented:\n \n \n \n \"\n \n We are very glad to see that the FDA is moving expeditiously to facilitate the supply of respiratory devices during the COVID-19 pandemic. \"\n \n \n \n \n \n About Tekcapital plc \n \n \n Tekcapital creates value from investing in new, university-developed intellectual properties and provides a range of IP investment services to make it easy for organisations to commercialise university-developed technology. Tekcapital is quoted on the AIM market of the London Sto...